To understand the stability of the anti-IFN-Abs, we assessed the kinetics of anti-IFN-Ab production, circulating IFNα levels, and disease activity in a longitudinal cohort (30 patients with SLE) over a 10-year period (cohort’s demographics is presented in Table S2). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.